Jean J. Zhao

This study identifies FGFR signaling as a driver of resistance and immune evasion in PIK3CA-driven serous-like endometrial cancer and shows that dual FGFR/PI3K inhibition improves tumor control.

This paper develops GT220, a selective PI3Kβ inhibitor, showing efficacy in PTEN-deficient cancers while sparing normal cells.

The paper demonstrates that statin-dye conjugates are selectively taken up by KRAS mutant cancer cells through enhanced macropinocytosis, enabling targeted killing of these cells without affecting KRAS wild-type cells.

This study identifies the IRG1/itaconate/NRF2/GSH axis in TAMs as a driver of PARPi resistance and immune evasion in BRCA1-deficient breast cancer, with pharmacological inhibition showing therapeutic potential.

This study shows CDK12 inhibition both downregulates and upregulates gene expression, with implications for cancer therapy.

This study shows that PTEN loss in cancer cells activates intrinsic interferon signaling, leading to immune resistance and vulnerability to CDK12 inhibition.

This study quantifies cell proliferation in tumors using multiplexed imaging and identifies spatial and temporal patterns of cell cycle regulation.

This study shows that paclitaxel induces cADPR production via Sarm1, increasing intra-axonal calcium and causing axon degeneration, with cADPR antagonists preventing neuropathy without affecting chemotherapy efficacy.

This study shows that targeting Nlgn3 secretion via ADAM10 inhibitors can block high-grade glioma growth in mouse models.